4 news items
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
IMCR
31 May 24
. Of the 47 monotherapy patients, 36 had a RECIST evaluable tumor assessment. The disease control rate (DCR), consisting of partial response (PR
Analyst Expectations For Immunocore Hldgs's Future
IMCR
24 May 24
.
Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform
Where Immunocore Hldgs Stands With Analysts
IMCR
29 Apr 24
. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates
Immunocore Hldgs Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
IMCR
11 Apr 24
statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights
- Prev
- 1
- Next